Literature DB >> 28831691

Parvovirus B19 infection associated with hemolytic anemia and cranial polyneuropathy.

João Sequeira1, Ana Calado2, Margarida Dias2, Manuel Manita2.   

Abstract

Parvovirus B19 (PB19) is a common, widespread, small, single-stranded DNA virus which has been linked with a broad spectrum of clinical illnesses, including a variety of neurological complications such as encephalitis, meningitis, myelitis, stroke, cerebellar ataxia, and neuropathy. The authors describe a case of PB19 infection associated with hemolytic anemia and cranial polyneuropathy involving the second and third cranial nerves in a 23-year-old immunocompetent woman. The diagnosis of acute PB19 infection was established with detection of positive DNA and anti-PB19 IgM antibodies in blood samples. Antiganglioside antibody studies were performed and serum anti-GD1b IgG was strongly positive. Further investigation was normal or negative, excluding other infectious or autoimmune disorders. The patient was initially treated with a 5-day course of intravenous immunoglobulin (IGIV). Because of incomplete neurological recovery, methylprednisolone was also administered 7 days after IGIV therapy initiation. Complete resolution of clinical symptoms was observed 3 months after disease onset at follow-up visit, despite the persistence of PB19 DNA and anti-PB19 IgM antibodies in serum 5 months after the initial presentation. Our report provides evidence that PB19 could affect both the central and peripheral nervous system, possibly by triggering an autoimmune mechanism that leads to autoantibody production.

Entities:  

Keywords:  Autoantibodies; Cranial neuropathy; Hemolytic anemia; Infection; Parvovirus B19

Mesh:

Substances:

Year:  2017        PMID: 28831691     DOI: 10.1007/s13365-017-0562-8

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  9 in total

1.  Multiple cranial nerve palsies: analysis of 979 cases.

Authors:  James R Keane
Journal:  Arch Neurol       Date:  2005-11

Review 2.  Clinical aspects of parvovirus B19 infection.

Authors:  K Broliden; T Tolfvenstam; O Norbeck
Journal:  J Intern Med       Date:  2006-10       Impact factor: 8.989

Review 3.  [A case of Guillain-Barré syndrome (GBS) following human parvovirus B19 infection].

Authors:  Y Yamaoka; E Isozaki; Y Kagamihara; S Matsubara; S Hirai; K Takagi
Journal:  Rinsho Shinkeigaku       Date:  2000-05

Review 4.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

5.  Parvovirus B19 clearance from peripheral blood after acute infection.

Authors:  M Musiani; M Zerbini; G Gentilomi; M Plazzi; G Gallinella; S Venturoli
Journal:  J Infect Dis       Date:  1995-11       Impact factor: 5.226

Review 6.  Neurologic manifestations associated with parvovirus B19 infection.

Authors:  Miltiadis Douvoyiannis; Nathan Litman; David L Goldman
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

Review 7.  Neurological manifestations of human parvovirus B19 infection.

Authors:  Faraj Barah; Pamela J Vallely; Graham M Cleator; Jonathan R Kerr
Journal:  Rev Med Virol       Date:  2003 May-Jun       Impact factor: 6.989

Review 8.  The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease.

Authors:  Jonathan R Kerr
Journal:  J Clin Pathol       Date:  2015-12-07       Impact factor: 3.411

Review 9.  Neurological aspects of human parvovirus B19 infection: a systematic review.

Authors:  Faraj Barah; Sigrid Whiteside; Sonia Batista; Julie Morris
Journal:  Rev Med Virol       Date:  2014-01-24       Impact factor: 6.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.